BR112022011052A2 - Tratamento para leucemia mieloide aguda ou síndrome mielodisplásica - Google Patents
Tratamento para leucemia mieloide aguda ou síndrome mielodisplásicaInfo
- Publication number
- BR112022011052A2 BR112022011052A2 BR112022011052A BR112022011052A BR112022011052A2 BR 112022011052 A2 BR112022011052 A2 BR 112022011052A2 BR 112022011052 A BR112022011052 A BR 112022011052A BR 112022011052 A BR112022011052 A BR 112022011052A BR 112022011052 A2 BR112022011052 A2 BR 112022011052A2
- Authority
- BR
- Brazil
- Prior art keywords
- myeloid leukemia
- myelodysplastic syndrome
- acute myeloid
- treatment
- lymphoma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944876P | 2019-12-06 | 2019-12-06 | |
| PCT/CA2020/051668 WO2021108918A1 (en) | 2019-12-06 | 2020-12-04 | Treatment for acute myeloid leukemia or myelodysplastic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022011052A2 true BR112022011052A2 (pt) | 2022-08-16 |
Family
ID=76221282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022011052A BR112022011052A2 (pt) | 2019-12-06 | 2020-12-04 | Tratamento para leucemia mieloide aguda ou síndrome mielodisplásica |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12533357B2 (enExample) |
| EP (1) | EP4069246A4 (enExample) |
| JP (1) | JP2023505301A (enExample) |
| KR (1) | KR20220124177A (enExample) |
| CN (1) | CN115397429A (enExample) |
| AU (1) | AU2020396807B2 (enExample) |
| BR (1) | BR112022011052A2 (enExample) |
| CA (1) | CA3163796A1 (enExample) |
| IL (1) | IL293623A (enExample) |
| MX (1) | MX2022006910A (enExample) |
| TW (1) | TWI880995B (enExample) |
| WO (1) | WO2021108918A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| TWI926033B (zh) | 2021-05-11 | 2026-05-21 | 美商歐瑞克製藥公司 | 類ｐｏｌｏ激酶４抑制劑 |
| TW202333712A (zh) * | 2021-12-22 | 2023-09-01 | 加拿大健康網路大學 | 於急性骨髓性白血病或淋巴瘤之治療 |
| CN117180295A (zh) * | 2023-09-13 | 2023-12-08 | 华东医院 | 一种用于治疗tp53突变髓系肿瘤的药物组合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010115279A1 (en) | 2009-04-06 | 2010-10-14 | University Health Network | Kinase inhibitors and method of treating cancer with same |
| TWI516262B (zh) | 2010-04-06 | 2016-01-11 | 健康網路大學 | 激酶抑制劑及以其治療癌症的方法 |
| CA2803446C (en) * | 2010-07-02 | 2019-06-04 | University Health Network | Use of plk4 antagonists for treating pten mutant diseases |
| WO2012048411A1 (en) * | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| EP3052102B1 (en) | 2013-10-04 | 2019-12-04 | Aptose Biosciences Inc. | Compositions for treating cancers |
| TR201902875T4 (tr) * | 2013-10-18 | 2019-03-21 | Univ Health Network | Plk-4 inhibitörünün tuz ve kristal formları. |
| WO2015116696A1 (en) | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| KR20190129889A (ko) | 2017-03-31 | 2019-11-20 | 노파르티스 아게 | 혈액 종양에서 HDM2-p53 상호작용 억제제의 용량 및 요법 |
| JP7343483B2 (ja) * | 2017-09-08 | 2023-09-12 | ユニバーシティー ヘルス ネットワーク | Ｐｏｌｏ様キナーゼ４の阻害のための併用療法 |
| US11612604B2 (en) * | 2017-12-06 | 2023-03-28 | Ludwig Institute For Cancer Research Ltd | Methods of treating cancer with PLK4 inhibitors |
| EP3959209A4 (en) | 2019-04-24 | 2022-12-28 | University Health Network | S4 CRYSTALLINE FORM OF A PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1H-IMIDAZOL-6-YL )-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE |
-
2020
- 2020-12-04 KR KR1020227023046A patent/KR20220124177A/ko active Pending
- 2020-12-04 CA CA3163796A patent/CA3163796A1/en active Pending
- 2020-12-04 JP JP2022534233A patent/JP2023505301A/ja active Pending
- 2020-12-04 AU AU2020396807A patent/AU2020396807B2/en active Active
- 2020-12-04 US US17/782,632 patent/US12533357B2/en active Active
- 2020-12-04 WO PCT/CA2020/051668 patent/WO2021108918A1/en not_active Ceased
- 2020-12-04 IL IL293623A patent/IL293623A/en unknown
- 2020-12-04 MX MX2022006910A patent/MX2022006910A/es unknown
- 2020-12-04 BR BR112022011052A patent/BR112022011052A2/pt unknown
- 2020-12-04 TW TW109142965A patent/TWI880995B/zh active
- 2020-12-04 CN CN202080095784.4A patent/CN115397429A/zh active Pending
- 2020-12-04 EP EP20895810.8A patent/EP4069246A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020396807A1 (en) | 2022-07-21 |
| JP2023505301A (ja) | 2023-02-08 |
| US12533357B2 (en) | 2026-01-27 |
| EP4069246A1 (en) | 2022-10-12 |
| MX2022006910A (es) | 2022-11-09 |
| US20230010772A1 (en) | 2023-01-12 |
| CA3163796A1 (en) | 2021-06-10 |
| IL293623A (en) | 2022-08-01 |
| CN115397429A (zh) | 2022-11-25 |
| EP4069246A4 (en) | 2023-12-06 |
| WO2021108918A1 (en) | 2021-06-10 |
| TW202134237A (zh) | 2021-09-16 |
| AU2020396807B2 (en) | 2026-07-16 |
| TWI880995B (zh) | 2025-04-21 |
| KR20220124177A (ko) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006908A (es) | Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo. | |
| MX2020011653A (es) | Métodos de tratamiento para el abuso de sustancias. | |
| MY208545A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| MY206796A (en) | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma | |
| MX2022006910A (es) | Tratamiento para la leucemia mieloide aguda o para el síndrome mielodisplásico. | |
| CY1117033T1 (el) | Αγωγη εναντι οξειας λεμφοβλαστικης λευχαιμιας | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| CR20200148A (es) | Compuestos monobactámicos cromados para el tratamiento de infecciones bacterianas | |
| EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
| BR112023010885A2 (pt) | Terapia de combinação de anti-cd19 | |
| EA201690608A1 (ru) | Способы лечения раковых заболеваний | |
| BR112023001615A2 (pt) | Tratamento para enxaqueca | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| EP3932917A3 (en) | Substituted phenyloxazolidinones for antimicrobial therapy | |
| BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
| PH12021550452A1 (en) | Methods of treating mycobacterial infections using tetracycline compounds | |
| MX2022005522A (es) | Formas de sal de un receptor de componente c5a de complemento. | |
| BR112021020962A2 (pt) | Métodos de tratamento de prurido | |
| PH12019501566A1 (en) | Amide compounds and use thereof | |
| EA201892098A1 (ru) | Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения | |
| MX2022006229A (es) | Composiciones y metodos para el tratamiento de resistencia a la insulina. | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| MX379576B (es) | Derivados de azetidina | |
| MX2021004085A (es) | El uso de un agonista inverso de h3r para el tratamiento de la somnolencia diurna excesiva asociada con la enfermedad de parkinson (ep). | |
| MY183483A (en) | Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |